Product Name | NebuSelect™ Recombinant Human VEGF165 |
---|---|
Catalog Number | NBL-240756 |
Alias/Synonyms | VEGF165; VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609 |
Appearance | see COA |
Molecule Weight | Ala27-Arg191 |
CAS | N/A |
Solubility | Water Soluble |
Storage | Short term 4℃; Long term -20℃. |
Shelf Life | 2 years |
Additional info 1 | P15692-4 |
Additional info 2 |
Catalog Numbe | Size | Price | Inventory Level | |
NBL-240756-100ug | 100ug | Inquire | Inquire | |
NBL-240756-1mg | 1mg | Inquire | Inquire | |
NBL-240756-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human VEGF165
Catalog#:
NBL-240756
Description:
NebuSelect™ Recombinant Human VEGF165(Cat#NBL-240756) is expressed in HEK293 without tag.It contains Ala27-Arg191.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 19.2 kDa. Due to glycosylation, the protein migrates to 20-30 kDa based on Bis-Tris PAGE result.
Target Name:
VEGF165; VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609
Target Information:
Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis.
Amino Acid Sequence:
Ala27-Arg191
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.